Testing COVID-19 therapies to prevent progression of mild disease

Letter/Communication

Open access

Marc Lipsitch, Stanley Perlman and Matthew K Waldor

The Lancet infectious diseases, Vol.20(12), pp.1367-1367

12/2020

DOI: 10.1016/S1473-3099(20)30372-8

PMCID: PMC7202831

PMID: 32618282

Files and links (1)

url

https://doi.org/10.1016/S1473-3099(20)30372-8View

Published (Version of record) Open Access

Comment | no abstract available

COVID-19

Betacoronavirus

Pandemics

Pneumonia, Viral - epidemiology

Humans

Title: Subtitle: Testing COVID-19 therapies to prevent progression of mild disease
Creators: Marc Lipsitch - Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Electronic address: mlipsitc@hsph.harvard.edu
Stanley Perlman - Department of Microbiology and Immunology and Department of Pediatrics, University of Iowa, Iowa City, IA, USA
Matthew K Waldor - Department of Medicine and Department of Microbiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Resource Type: Letter/Communication
Publication Details: The Lancet infectious diseases, Vol.20(12), pp.1367-1367
Publisher: United States
DOI: 10.1016/S1473-3099(20)30372-8
PMID: 32618282
PMCID: PMC7202831
ISSN: 1473-3099
eISSN: 1474-4457
Grant note: R01 AI042347 / NIAID NIH HHS
Language: English
Date published: 12/2020
Academic Unit: Microbiology and Immunology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Infectious Disease (Pediatrics)
Record Identifier: 9984070293502771

9 Record Views